ExploCap™ Technology

OZB ExploCap™ RNAs are produced by in vitro transcription and are co-transcriptionnaly capped using trinucleotides ExploCap analog (equivalent to CleanCap®) and contain a poly(A) tail at the 3’ end. Sequences have been optimized to yield improved stability and performance.

ExploCap™ is a next-generation co-transcriptional capping reagent designed to generate high-quality capped mRNA with excellent biological properties.

High-quality RNA capping plays a central role in mRNA & saRNA performance, as it directly impacts:

• RNA quality,

• translation efficiency,

• degradation risk by skipping a production step,

• downstream manufacturability.

ExploRNA’s next-generation capping reagent ExploCap™ has been designed to flexibly fit various in vitro transcription (IVT) workflows providing reliable high-quality outcomes. ExploCap™ supports both unmodified and modified RNA, and provides a cost-effective alternative to industry-standard capping reagents.

ExploCap Structure

ExploCap Structure

ExploCap mRNAs resemble fully matured mRNAs with 5’cap structure and 3’ polyA tail, therefore ready to be translated by the ribosome. ExploCap is a proprietary ExploRNA cap with properties similar to Cap 1.

ARCA CAP1 ExploCap™ CleanCap®
Capping efficiency 60-80% 95-99% 95-99% 95-99%
Transcription Yield Low High High High

ExploCap™ and CleanCap® show comparable mRNA transfection performance

cleancap ag

Figure 1: DC2.4 cells transfected with GFP mRNA (100 ng/well, 96-well plate) using RmesFect transfection reagent at a 3.5 µl:1 µg ratio. Cells were analyzed after 24h of incubation.

CleanCap® is a proprietary technology of TriLink Biotechnologies.

ExploCap™ and Cap1 show comparable in vivo performance

cap analog in vivo delivery
cap reagent ag

Figure 2: mRNA: human EPO, non-modified U | Dose: 1 µg | Cap: Cap 1, ExploCap®. LNP: 3 different clinical grade formulations | Route: intravenous. Data provided by ExploRNA Therapeutics.

ExploCap™ technology is licensed to OZ Biosciences by ExploRNA Therapeutics and is protected under patent WO2021162566.

ExploCap is the intellectual property of ExploRNA Therapeutics.

All RNA products incorporating ExploCap are supplied for Research Use Only (RUO) and are not intended for diagnostic, therapeutic, or clinical use.

ExploRNA

Explocap™ Cap Analog

Explore our Webinar on mRNA platform: Explocap™, a new cap analog to extend synthesis capabilities

Discover our mRNA custom platform, with an overview of our synthesis capabilities and available modifications. ExploRNA Therapeutics introduce ExploCap™ and other cap analogs, supported by concrete in vivo data.

Watch

Capped mRNAs

ExploCap™ mRNAs are available in unmodified, modified with 5moU or N1-mψ to reduce innate immune responses.

All our messenger RNAs catalog are available capped with ExploCap analog upon request.

ExploCap™ mRNA results

Comparison of transfection efficiency of mRNA capped with Cap1 and ExploCap™ in hek293 cells

cap analog egfp mrna

Figure 3: HEK293 cultivated in 96-well plates were transfected with 100 ng mRNA encoding for GFP and capped with Cap1 or ExploCap™. 24 H after transfection, GFP expression was visualised under fluorescence microscopie (A) and fluorescence intensity was quantified by flow cytometry (B).

Comparison of transfection efficiency of mRNA capped with Cap1 and ExploCap™ in various cell lines (Vero, C6 and C2C12)

cap analog egfp mrna in cell linesegfp mrna capped with explocap

Figure 4: Vero C6 and C2C12 cell lines cultivated in 96-well plates were transfected with 100 ng mRNA encoding for GFP and capped with Cap1 or ExploCap™. 24 H after transfection, GFP expression was visualised under fluorescence microscopie (A) and % of GFP positive cells (B) and fluorescence intensity (C) were quantified by flow cytometry.

Catalog mRNAs

Capped saRNAs

ExploCap™ saRNAs are available in unmodified or modified with m5C.

All our self-amplifying RNAs catalog are available capped with ExploCap analog upon request.

ExploCap™ saRNA results

Comparison of transfection efficiency of saRNA capped with Cap1 and ExploCap in hek293 cells

capped sarna encoding egfp protein

Figure 4: HEK293 cultivated in 96-well plates were transfected with 100 ng saRNA encoding for GFP and capped with Cap1 or ExploCap™ using Rmesfect at a 3.5:1 ratio. GFP expression was visualised under fluorescence microscopie at day 1 (D1) and day 6 (D6) after transfection.

Catalog saRNAs

ExploCap™ GFP mRNA

ExploCap™ mRNA

Unmodified / 5-methoxyuridine / N1-methylpseudouridine

ExploCap™ OVA mRNA

ExploCap™ mRNA

Unmodified / 5-methoxyuridine / N1-methylpseudouridine

Unmodified / 5-methoxyuridine / N1-methylpseudouridine

ExploCap™ GFP saRNA

ExploCap™ saRNA

Unmodified / m5C 

ExploCap™ F-Luc mRNA

ExploCap™ mRNA

Unmodified / 5-methoxyuridine / N1-methylpseudouridine